CAMBRIDGE, Mass., April 22, 2024 Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral.
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences
Editas Medicine Highlights 2024 Anticipated Milestones And Strategic Priorities At The J.P. Morgan Healthcare Conference menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.